Prospective, randomized, open-label,clinical trial comparing the effects of astaxanthin and placebo on blood pressure, endothelial function and makers for cardiovascular diseases

Prospective, randomized, open-label,clinical trial comparing the effects of astaxanthin and placebo on blood pressure, endothelial function and makers for cardiovascular diseases - Effects of astaxanthin on blood pressure and endothelial function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020782

Enrollment

Registered

2016-01-29

Start date

2016-01-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

astaxanthin tablet 1tab/day for 12 weeks &gt

placebo 1tab/day for 12 weeks placebo 1tab/day for 12 weeks &gt

astaxanthin tablet 1tab/day for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) hypertensive patients on treatment 2) Out patients

Exclusion criteria

Exclusion criteria: 1) Poor-controlled hypertension (DBP>110) 2) Poor-controlled diabetes (HbA1c>8.0 %) 3) Secondary hypertension 4) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 5) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 6) End stage renal disease 7) Symptomatic (NYHA III or IV) congestive heart failure 8) Malignancies or other diseases with poor prognosis 9) Subjects whose doctor in charge do not agree to join the trial

Design outcomes

Primary

Measure	Time frame
Blood pressure (On visit/Home monitoring/24 hr ambulatory) Flow-mediated vasodilation in forearm Heparin-releasable EC-SOD levels 12 weeks after administration	—

Secondary

Measure	Time frame
Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria) 12 weeks after administration	—

Countries

Japan

Contacts

Public ContactMakoto Ayaori

National Defense Medical College Department of Internal Medicine

ayaori@ndmc.ac.jp04-2995-1617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026